Qianqian Song

Qing Wang, Tianshi Liu, Minghao Zhou et al.

Systematic characterization of drug-disease relationships is essential for drug discovery and repurposing, yet is hindered by the heterogeneity and rapid growth of biomedical literature. Existing datasets rely on labor-intensive curation and are often incomplete, while LLM-only approaches suffer from hallucination and weak evidence grounding. We introduce UniD$^3$, a unified framework that integrates Large Language Models with Knowledge Graph-enhanced Retrieval-Augmented Generation (KG-RAG) to extract, organize, and validate drug-disease knowledge across Drug-Disease Matching (DDM), Drug Effectiveness Assessment (DEA), and Drug-Target Analysis (DTA). UniD$^3$ processes 157,849 PubMed articles with Llama 3.3-70B and constructs knowledge graphs via a dual-stage strategy combining paper-level extraction with KG-level consolidation centered on drug and disease entities. These graphs support KG-RAG-based generation of structured datasets, evaluated through external benchmarks, fuzzy matching with curated resources, and clinician review. UniD$^3$ produces six knowledge graphs and large-scale datasets, including 28,915 DDM, 15,042 DEA, and over 4,000 DTA QA pairs. External validation shows strong performance (F1: 0.85-0.87 for DDM/DEA; 0.82 for DTA), with clinician review confirming high reliability (AUROC = 0.90). KG-RAG-augmented models outperform standalone LLMs, and the UniD$^3$ chatbot enables interpretable, citation-supported exploration of drug-disease relationships. UniD$^3$ provides a scalable, extensible framework for transforming unstructured biomedical literature into high-quality, structured drug-disease knowledge, supporting AI-driven discovery, repurposing, and precision medicine.

Qing Wang, Bo Li, Jialu Liang et al.

Drug-information question answering is a high-stakes setting where hallucinated facts can mislead clinical decision-making and the provenance of each cited fact matters as much as the fact itself. We present DrugClaw, a multi-agent retrieval-augmented system that queries a registry of drug and pharmacovigilance skills via a reflection-driven state-machine workflow and returns answers grounded in primary regulatory or peer-reviewed records. We also contribute DrugAudit, a 3,772-item authority-aware benchmark with an evaluation panel that scores upstream-of-gold source match, token-level semantic snippet overlap, and citation faithfulness under a dual-judge LLM-as-judge protocol with inter-judge kappa = 0.88 (almost-perfect). Across DrugAudit plus drug-related subsets of MedQA (751) and PubMedQA (512), DrugClaw is top-1 on every column of the headline table: composite Evidence Index under both judges, judge-mediated answer correctness, primary-source rate (0.918, +10.1 pp over next-best), faithfulness (0.887, +5.9 pp), MedQA (0.920), and PubMedQA (0.693).

Enze Xu, Jingwen Zhang, Jiadi Li et al.

Alzheimer's disease (AD) is a heterogeneous, multifactorial neurodegenerative disorder characterized by beta-amyloid, pathologic tau, and neurodegeneration. There are no effective treatments for Alzheimer's disease at a late stage, urging for early intervention. However, existing statistical inference approaches of AD subtype identification ignore the pathological domain knowledge, which could lead to ill-posed results that are sometimes inconsistent with the essential neurological principles. Integrating systems biology modeling with machine learning, we propose a novel pathology steered stratification network (PSSN) that incorporates established domain knowledge in AD pathology through a reaction-diffusion model, where we consider non-linear interactions between major biomarkers and diffusion along brain structural network. Trained on longitudinal multimodal neuroimaging data, the biological model predicts long-term trajectories that capture individual progression pattern, filling in the gaps between sparse imaging data available. A deep predictive neural network is then built to exploit spatiotemporal dynamics, link neurological examinations with clinical profiles, and generate subtype assignment probability on an individual basis. We further identify an evolutionary disease graph to quantify subtype transition probabilities through extensive simulations. Our stratification achieves superior performance in both inter-cluster heterogeneity and intra-cluster homogeneity of various clinical scores. Applying our approach to enriched samples of aging populations, we identify six subtypes spanning AD spectrum, where each subtype exhibits a distinctive biomarker pattern that is consistent with its clinical outcome. PSSN provides insights into pre-symptomatic diagnosis and practical guidance on clinical treatments, which may be further generalized to other neurodegenerative diseases.

Qing Wang, Yining Pan, Minghao Zhou et al.

Drug resistance presents a major challenge in cancer therapy. Single cell profiling offers insights into cellular heterogeneity, yet the application of large-scale foundation models for predicting drug response in single cell data remains underexplored. To address this, we developed scDrugMap, an integrated framework featuring both a Python command-line interface and a web server for drug response prediction. scDrugMap evaluates a wide range of foundation models, including eight single-cell models and two large language models, using a curated dataset of over 326,000 cells in the primary collection and 18,800 cells in the validation set, spanning 36 datasets and diverse tissue and cancer types. We benchmarked model performance under pooled-data and cross-data evaluation settings, employing both layer freezing and Low-Rank Adaptation (LoRA) fine-tuning strategies. In the pooled-data scenario, scFoundation achieved the best performance, with mean F1 scores of 0.971 (layer freezing) and 0.947 (fine-tuning), outperforming the lowest-performing model by over 50%. In the cross-data setting, UCE excelled post fine-tuning (mean F1: 0.774), while scGPT led in zero-shot learning (mean F1: 0.858). Overall, scDrugMap provides the first large-scale benchmark of foundation models for drug response prediction in single-cell data and serves as a user-friendly, flexible platform for advancing drug discovery and translational research.

Bo Li, Bob Zhang, Chengyang Zhang et al.

In the field of image-based drug discovery, capturing the phenotypic response of cells to various drug treatments and perturbations is a crucial step. However, existing methods require computationally extensive and complex multi-step procedures, which can introduce inefficiencies, limit generalizability, and increase potential errors. To address these challenges, we present PhenoProfiler, an innovative model designed to efficiently and effectively extract morphological representations, enabling the elucidation of phenotypic changes induced by treatments. PhenoProfiler is designed as an end-to-end tool that processes whole-slide multi-channel images directly into low-dimensional quantitative representations, eliminating the extensive computational steps required by existing methods. It also includes a multi-objective learning module to enhance robustness, accuracy, and generalization in morphological representation learning. PhenoProfiler is rigorously evaluated on large-scale publicly available datasets, including over 230,000 whole-slide multi-channel images in end-to-end scenarios and more than 8.42 million single-cell images in non-end-to-end settings. Across these benchmarks, PhenoProfiler consistently outperforms state-of-the-art methods by up to 20%, demonstrating substantial improvements in both accuracy and robustness. Furthermore, PhenoProfiler uses a tailored phenotype correction strategy to emphasize relative phenotypic changes under treatments, facilitating the detection of biologically meaningful signals. UMAP visualizations of treatment profiles demonstrate PhenoProfiler ability to effectively cluster treatments with similar biological annotations, thereby enhancing interpretability. These findings establish PhenoProfiler as a scalable, generalizable, and robust tool for phenotypic learning.

Qianqian Song

Low rank matrix approximation is a popular topic in machine learning. In this paper, we propose a new algorithm for this topic by minimizing the least-squares estimation over the Riemannian manifold of fixed-rank matrices. The algorithm is an adaptation of classical gradient descent within the framework of optimization on manifolds. In particular, we reformulate an unconstrained optimization problem on a low-rank manifold into a differential dynamic system. We develop a splitting numerical integration method by applying a splitting integration scheme to the dynamic system. We conduct the convergence analysis of our splitting numerical integration algorithm. It can be guaranteed that the error between the recovered matrix and true result is monotonically decreasing in the Frobenius norm. Moreover, our splitting numerical integration can be adapted into matrix completion scenarios. Experimental results show that our approach has good scalability for large-scale problems with satisfactory accuracy

Qianqian Song

In recent years, large-scale Bayesian learning draws a great deal of attention. However, in big-data era, the amount of data we face is growing much faster than our ability to deal with it. Fortunately, it is observed that large-scale datasets usually own rich internal structure and is somewhat redundant. In this paper, we attempt to simplify the Bayesian posterior via exploiting this structure. Specifically, we restrict our interest to the so-called well-clustered datasets and construct an \emph{approximate posterior} according to the clustering information. Fortunately, the clustering structure can be efficiently obtained via a particular clustering algorithm. When constructing the approximate posterior, the data points in the same cluster are all replaced by the centroid of the cluster. As a result, the posterior can be significantly simplified. Theoretically, we show that under certain conditions the approximate posterior we construct is close (measured by KL divergence) to the exact posterior. Furthermore, thorough experiments are conducted to validate the fact that the constructed posterior is a good approximation to the true posterior and much easier to sample from.